A new source of growth funding for Finnish life science innovations – a second fund by Hadean Ventures

  • Share on Twitter
  • Share on LinkedIn

Oslo-based but with international operations, Hadean Ventures announces the final closing of its second fund. The fund closes at EUR 144 million, substantially over the target of EUR 125 million.

The fund invests in life sciences, including pharma, biotech, medtech, diagnostics and digital health. It will invest in European startups either in their early or later growth stages, with special interest in Nordic startups as well as startups from German-speaking regions.

We are pleased to be a new investor in Hadean Capital II. With Finland as part of Hadean’ core geographical focus, the Finnish life science operators now have a chance to tap into Haden Ventures’ international expertise,” elaborates Tapio Passinen the reasons for Tesi’s investment commitment.

Tesi did not invest in the first fund by Hadean Ventures.

Read more:

Additional information:

Tapio Passinen, Investment Director, Fund Investments
+358 40 840 3681


Tesi (officially Finnish Industry Investment Ltd) is a state-owned, market-driven investment company that invests in venture capital and private equity funds and directly in Finnish startups and growth companies. tesi.fi | X (Twitter) | LinkedIn | Newsletter